Oncogenic Ras abrogates MEK SUMOylation that suppresses the ERK pathway and cell transformation

Abstract

Oncogenic Ras is known to activate the Raf–MEK–ERK phosphorylation cascade to promote mitogenic signalling. Ras also inhibits the downregulation of MAPK pathway activity by preventing the MEKK1 SUMO E3 ligase from sumoylating and inactivating MEK. The ERK (extracellular signal-regulated kinase) MAPK (mitogen-activated protein kinase) cascade (Raf–MEK–ERK) mediates mitogenic signalling, and is frequently hyperactivated by Ras oncogenes in human cancer. The entire range of activities of multifunctional Ras in carcinogenesis remains elusive. Here we report that the ERK pathway is downregulated by MEK (MAPK–ERK kinase) SUMOylation, which is inhibited by oncogenic Ras. MEK SUMOylation blocked ERK activation by disrupting the specific docking interaction between MEK and ERK. Expression of un-SUMOylatable MEK enhanced ERK activation, cell differentiation, proliferation and malignant transformation by oncogenic ErbB2 or Raf, but not by active Ras. Interestingly, MEK SUMOylation was abrogated in cancer cells harbouring Ras mutations. Oncogenic Ras inhibits MEK SUMOylation by impairing the function of the MEKK1 MAPKKK as a SUMO-E3 ligase specific for MEK. Furthermore, forced enhancement of MEK SUMOylation suppressed Ras-induced cell transformation. Thus, oncogenic Ras efficiently activates the ERK pathway both by activating Raf and by inhibiting MEK SUMOylation, thereby inducing carcinogenesis.

Cite this article

Kubota, Y., O’Grady, P., Saito, H. et al. Oncogenic Ras abrogates MEK SUMOylation that suppresses the ERK pathway and cell transformation. Nat Cell Biol 13, 282–291 (2011). https://doi.org/10.1038/ncb2169

View full text

>> Full Text:   Oncogenic Ras abrogates MEK SUMOylation that suppresses the ERK pathway and cell transformation